Abstract 485P
Background
Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly improved progression-free survival (PFS) compared with chemotherapy. We report results from a retrospective study of first-line afatinib in Korean patients with EGFR M+ NSCLC in real-world setting of two hospitals in South Korea.
Methods
Clinical data of Korean patients with stage IV EGFR M+ NSCLC who received first-line afatinib treatment in Pusan National University Yangsan Hospital and Pusan National University Hospital between February 2015 to December 2016 were obtained. Objective response rate (ORR), disease control rate (DCR), PFS, and tolerability were assessed. The treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). PFS was estimated by Kaplan-Meier method and the differences in survival were assessed by log-rank test.
Results
A total of 99 eligible patients were enrolled for analysis. Mean age was 68 years (range: 35-83 years) and 56.6% were female. A total of 96.0% patients were histologically diagnosed with adenocarcinoma with 52.0% brain metastases (BM). ORR was 63.4% and DCR was 93.5%. Intracranial response was 69.6% in patients treated with afatinib plus local therapy and 55.0% with afatinib therapy alone. Median PFS reached 15.1 (95% CI: 12.6-17.4) months in overall, 12.6 (9.9-14.5) months in exon 19 deletion, 16.9 (12.5-21.1) months in exon 21 L858R mutation, 13.1 (1.9 to 22.3) months in rare mutations, 18.6 (14.9-24.2) months in BM absent, and 12.2 (10.9-15.2) months BM present. There is no significantly difference between PFS either by mutation types or by BM status. The most common Grade ≥3 side effects were skin rash/acne (15.2%), and diarrhea (10.1%).
Conclusions
This study indicates that the clinical outcomes achieved with first-line afatinib in Korean patients in real-world setting appear to be better than observed from the LUX-Lung studies. Afatinib can also provide a good intracranial response in patients with brain metastases regardless of whether or not they also receive local treatment.
Clinical trial identification
Editorial acknowledgement
Dr. Luke for the review and helpful comments for this study.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract